Jeena Sikho LifecareNSE:JSLL +0.29%87 Debt-to-EBITDA is 0.39 as of Mar. 2026, which is 5% above its 10-year median of 0.37. GuruFocus rates NSE:JSLL with a GF Score™ of 87/100 and a GF Value™ of ₹774.77 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 475 Healthcare Providers & Services companies, Jeena Sikho Lifecare ranks better than 84.63% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Jeena Sikho Lifecare's Debt-to-EBITDA or its related term are showing as below:
NSE:JSLL'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.01 Med: 0.37 Max: 1.47
Current: 0.36
During the past 8 years, the highest Debt-to-EBITDA Ratio of Jeena Sikho Lifecare was 1.47. The lowest was 0.01. And the median was 0.37.
NSE:JSLL's Debt-to-EBITDA is ranked better than 84.63% of 475
companies
in the Healthcare Providers & Services industry
Industry Median: 2.21
vs NSE:JSLL: 0.36
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Jeena Sikho Lifecare Debt-to-EBITDA Related Terms
Jeena Sikho Lifecare Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Jeena Sikho Lifecare's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:JSLL vs HCA, THC, DVA: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Jeena Sikho Lifecare's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jeena Sikho Lifecare Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Jeena Sikho Lifecare's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Jeena Sikho Lifecare's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Jeena Sikho Lifecare (NSE:JSLL) has a Debt-to-EBITDA of 0.39 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Jeena Sikho Lifecare. This is near median its historical median of 0.37. Over the past decade, Jeena Sikho Lifecare's Debt-to-EBITDA has ranged from 0.01 to 1.47. According to the industry distribution chart, Jeena Sikho Lifecare ranks #73 out of 475 companies in the Healthcare Providers & Services industry, placing it in the top 15.4%.
Is Jeena Sikho Lifecare's Debt-to-EBITDA too high?
Jeena Sikho Lifecare's current Debt-to-EBITDA of 0.39 is near median its 10-year median of 0.37. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 1.47. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.21. Jeena Sikho Lifecare's value of 0.39 is 82.4% below this industry median. Based on the distribution chart, Jeena Sikho Lifecare ranks #73 out of 475 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Jeena Sikho Lifecare has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jeena Sikho Lifecare's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Jeena Sikho Lifecare ranks #73 out of 475 companies for Debt-to-EBITDA. This places Jeena Sikho Lifecare in the top 15% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 2.21. Jeena Sikho Lifecare's value of 0.39 is 82.4% below this benchmark. Historically, Jeena Sikho Lifecare's own Debt-to-EBITDA has ranged from 0.01 to 1.47 over the past decade. While the company's 10-year median is 0.37 vs. the industry median of 2.21, Jeena Sikho Lifecare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.21, based on 475 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jeena Sikho Lifecare's current Debt-to-EBITDA of 0.39 is 82.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Jeena Sikho Lifecare. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jeena Sikho Lifecare's current Debt-to-EBITDA is 0.39, which is near median its own 10-year median of 0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jeena Sikho Lifecare stock overvalued right now?
Based on GuruFocus' analysis, Jeena Sikho Lifecare (NSE:JSLL) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹774.77, compared to a current price of ₹576.05 — trading 25.6% below its estimated fair value. The current Debt-to-EBITDA is 0.39, which is near median its 10-year median of 0.37 and 82.4% below the Healthcare Providers & Services industry median of 2.21. Jeena Sikho Lifecare's overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Jeena Sikho Lifecare (NSE:JSLL), the current Debt-to-EBITDA is 0.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jeena Sikho Lifecare (NSE:JSLL) Overvalued in 2026?
Based on GuruFocus' analysis, Jeena Sikho Lifecare stock appears to be undervalued.
The current stock price of ₹576.05 is trading 25.6% below its estimated GF Value™ of ₹774.77.
GuruFocus considers Jeena Sikho Lifecare to be Modestly Undervalued.
Key valuation signals for NSE:JSLL:
Debt-to-EBITDA: 0.39 (near median its 10-year median of 0.37)
GF Value™: ₹774.77 vs. price of ₹576.05 (25.6% below fair value)
Industry Position: 82.4% below the Healthcare Providers & Services median (#73 of 475)
No single metric tells the full story. See the NSE:JSLL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jeena Sikho Lifecare Ltd provides Ayurvedic healthcare products and services. The company operates only in one business segment which is Trading of Ayurvedic Medicines and providing Ayurvedic therapies. The company engages in conducting health check-up camps, and free yoga sessions to make people aware of health problems. It offers a wide range of Ayurvedic products such as Shuddhi 32 Herbs Tea, Shuddhi Addiction Free Kit, Shuddhi BP Package, Shuddhi Diabetes Care Package, and Shuddhi Divya Sanjeevani-Anti-Viral Package.
87GF Score
Get the complete analysis for NSE:JSLL
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:JSLL has been successfully added to your 
